Alcohol Dependence Clinical Trial
Official title:
Zonisamide in Addition to Enhanced Cognitive Processing Therapy-C (E-CPT-C) for Veterans With PTSD and Comorbid Alcohol Dependence
Verified date | March 2020 |
Source | Yale University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a randomized, controlled trial with 50 veterans diagnosed with post-traumatic stress disorder (PTSD) and comorbid alcohol dependence. Veterans will be randomized to receive either zonisamide (400 mg) or placebo for 12 weeks in a double blind fashion. Randomization will be done using 3:1 ratio and will be performed by our research pharmacy using a random assignment in blocks of 4- 3 will be assigned to active medication and 1 to placebo. Medication will be titrated over a 6 week titration phase followed by a 6 week treatment phase. All veterans will receive E-CPT-C therapy for the 12 weeks of treatment; E-CPT-C will be provided by trained and qualified clinicians with extensive experience providing E-CPT-C. Veterans will be recruited primarily through advertisement, but also through the clinical facilities at the VA and from other collaborators.
Status | Completed |
Enrollment | 24 |
Est. completion date | January 1, 2019 |
Est. primary completion date | January 1, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Current alcohol dependence, as determined by a structured clinical interview (Structured Clinical Interview for DSM-IV Axis I Disorders) (SCID) - Current PTSD as determined by a structured clinical interview (SCID) - Veterans with current alcohol dependence, with at least one recent episode of heavy drinking over the past 14 days. - Medically and neurologically healthy on the basis of history, physical examination, EKG, screening laboratories - For women, negative pregnancy test and use of acceptable method of contraception Exclusion Criteria: - Females who are pregnant or lactating. - Veterans with a current unstable medical condition such as neurological, cardiovascular, endocrine, renal, liver, or thyroid pathology, which in the opinion of the physician would preclude the subject from fully cooperating or be of potential harm during the course of the study - Veterans who meet current SCID criteria for a major Axis I diagnosis (Bipolar Disorders, Schizophrenia and Schizophrenia-type Disorders). - History of substance dependence (other than alcohol, tobacco or cannabis) by DSM-IV criteria in the last 90 days. - Veterans taking mood stabilizers and antipsychotic medications for specific psychiatric disorders. - Veterans with a history of allergy to zonisamide. - Veterans already receiving CPT. |
Country | Name | City | State |
---|---|---|---|
United States | VA Connecticut Healthcare System | West Haven | Connecticut |
Lead Sponsor | Collaborator |
---|---|
Yale University | United States Department of Defense |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Drinking Days | Using a 90 day Timeline Follow Back (TLFB), the total number of drinking days at baseline and at 12 weeks of treatment were used. | 12 weeks | |
Primary | Number of Heavy Drinking Days | Timeline Follow Back (TLFB) will be used to document the number of "heavy" drinking days during 12 weeks of treatment. Heavy drinking is defined as greater than or equal to 5 drinks for men and greater than or equal to 4 drinks for women. | 12 weeks | |
Primary | Clinician-Administered PTSD Scale (CAPS) Total Score | The Clinician-Administered PTSD Scale (CAPS) Total Score will be used to measure PTSD symptoms at the end of the 12 week intervention. The CAPS Total Score is a summing of the 17 items that are each scored 0-4- where 0 indicates "none". The range of Total Scores can be 0 to 136, where 136 would be the highest amount of scored PTSD symptoms. | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03340051 -
Remote Alcohol Monitoring and Episodic Thinking
|
N/A | |
Completed |
NCT02901041 -
Interdisciplinary Study of A Novel Anticonvulsant in Alcoholism
|
Phase 3 | |
Not yet recruiting |
NCT06444243 -
Psilocybin-assisted Therapy for Alcohol Use Disorder
|
Phase 2 | |
Completed |
NCT02486900 -
Neurofeedback & Alcohol Dependence
|
N/A | |
Completed |
NCT02705898 -
Lifestyle Physical Activity Intervention for Depressed Alcohol Dependent Women
|
N/A | |
Completed |
NCT02197598 -
Treatment of Patients Suffering of Alcohol Dependence and Impaired Liver Function With Selincro® As-needed Use
|
Phase 4 | |
Completed |
NCT02179749 -
Mifepristone Treatment of Alcohol Use Disorder
|
Phase 2 | |
Recruiting |
NCT02385643 -
The Efficacy of A Smartphone-based Support System to Reinforce Alcohol Abstinence in Treatment-seeking Patients
|
N/A | |
Completed |
NCT01828866 -
Eye Movement Desensitization and Reprocessing (EMDR) in Alcohol Dependent Patients
|
N/A | |
Terminated |
NCT01408641 -
Topiramate for Alcohol Use in Posttraumatic Stress Disorder
|
N/A | |
Active, not recruiting |
NCT01182766 -
New Treatment for Alcohol and Nicotine Dependence
|
Phase 2/Phase 3 | |
Completed |
NCT02193204 -
Chronic Alcohol, Stress Inflammatory Response and Relapse Risk
|
N/A | |
Completed |
NCT01342549 -
Treatment Strategy for Alcohol Use Disorders in Veterans With TBI
|
Phase 3 | |
Completed |
NCT01176591 -
HBPL Study of the Impact of the NK1 Antagonist Aprepitant
|
Phase 2 | |
Completed |
NCT01165541 -
A Study of Quetiapine and Mirtazapine for the Treatment of Alcohol Dependency
|
Phase 2 | |
Completed |
NCT00585780 -
Prazosin to Reduce Stress-Induced Alcohol/Drug Craving and Relapse
|
Phase 1/Phase 2 | |
Completed |
NCT01056484 -
Mindfulness Meditation for Health
|
Phase 2 | |
Completed |
NCT00607620 -
Disseminating Organizational SBI Services at Trauma Centers
|
N/A | |
Completed |
NCT00884884 -
Aripiprazole and Topiramate on Free-Choice Alcohol Use
|
Phase 2/Phase 3 | |
Completed |
NCT00463346 -
Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism
|
Phase 3 |